Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 22, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details changes in shareholdings within the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from fund movements and re-valuations on July 15, 2005:
- Plan Fund Movement: The number of Ordinary Share ADRs held by the fund increased from 18,322,085 to 18,371,975 at an average price of $48.50.
- Notional Allocation Increase: A re-valuation of the cash element of the notional investment resulted in an increase in the notional allocation of Ordinary Share ADRs for Russell Greig at a price of $47.99 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports on compliance with Disclosure rule 3.1.4R(1)(b) and 3.1.4R(1)(a) regarding the transactions noted above.
Key Facts for Investor Verification
- Directors Dr J P Garnier and Dr T Yamada are potentially interested in the shares held in the US Retirement Savings Plan as beneficiaries.
- The increase in the Plan's ADR holdings was driven by a fund movement on July 15, 2005.
- Russell Greig received a notification of an increased notional allocation of ADRs following a re-valuation.
- The transactions were notified to the Company on July 21, 2005, by the Company Secretary, S M Bicknell.